Lataa...
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
Idelalisib is a targeted agent that potently inhibits PI3Kδ which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL). Both these agents are FDA-approved for C...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369961/ https://ncbi.nlm.nih.gov/pubmed/28187444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15180 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|